Our infographic spotlights key trends in the global market for cerebral aneurysm and arteriovenous malformation (AVM) embolization systems, which is expected to reach $1.2bn by 2022, a CAGR of 3.9% from $975m in 2017. Among the growth drivers is the improvement of imaging screening techniques in developed nations. While this has resulted in increased intervention for cerebral aneurysm and AVM embolization, routine screening is not practiced, even in developed nations. Embolic coils accounted for the majority of sales with an estimated 73% market share. Meanwhile, a growing number of improved and premium-priced products such coil-assisted stent products and advanced embolic coil designs and flow diversion products are driving up the total value of the market.
For a more in-depth look at the market, check out Meddevicetracker's report "Interventional Neurology: Cerebral Aneurysm and Arteriovenous Malformation Embolization Systems."
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.
After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.
Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.
